CCIA
GNMK

Campbell & Co Investment Adviser’s GenMark Diagnostics, Inc GNMK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-25,481
Closed -$181K – 762
2019
Q1 		$181K Buy
25,481
+9,882
+63% +$65.1K 0.09% 463
2018
Q4 		$84K Buy
+15,599
New +$81.2K 0.08% 311

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Campbell & Co Investment Adviser's GNMK Position: Q2 2019 in Review

Campbell & Co Investment Adviser sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2019, closing a stake of 25,481 shares — an estimated $181K sold.

Campbell & Co Investment Adviser first reported a position in GNMK in Q4 2018 and held it in 2 quarters. The position peaked at $181K in Q1 2019. 106 funds tracked by Wall St. Rank hold GNMK as of Q2 2019.

  • Campbell & Co Investment Adviser reported no remaining GenMark Diagnostics, Inc position as of Q2 2019 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 25,481 GenMark Diagnostics, Inc shares in Q2 2019, an estimated $181K.
  • Campbell & Co Investment Adviser first reported a position in GenMark Diagnostics, Inc in Q4 2018 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's GenMark Diagnostics, Inc position peaked at $181K in Q1 2019.
  • 106 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2019.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2019, filed 10 Jul 2019.